Menu Search
Equities

Rigel Pharmaceuticals Inc

RIGL:NSQ

Rigel Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)26.09
  • Today's Change0.05 / 0.19%
  • Shares traded234.73k
  • 1 Year change+150.87%
  • Beta1.1294
Data delayed at least 15 minutes, as of Nov 25 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Rigel Pharmaceuticals Inc had relatively flat revenues (120.24m to 116.88m), though the company grew net income from a loss of 58.57m to a smaller loss of 25.09m. A reduction in the selling, general and administrative costs as a percentage of sales from 93.52% to 90.47% was a component in the net income growth despite flat revenues.
Gross margin89.43%
Net profit margin2.46%
Operating margin6.03%
Return on assets3.05%
Return on equity--
Return on investment5.10%
More ▼

Cash flow in USDView more

In 2023, Rigel Pharmaceuticals Inc increased its cash reserves by 34.04%, or 8.33m. Cash Flow from Financing totalled 18.37m or 15.71% of revenues. In addition the company used 5.74m for operations while cash used for investing totalled 4.30m.
Cash flow per share0.3306
Price/Cash flow per share79.11
Book value per share-0.831
Tangible book value per share-2.40
More ▼

Balance sheet in USDView more

Rigel Pharmaceuticals Inc has a Debt to Total Capital ratio of 132.43%.
Current ratio1.96
Quick ratio1.87
Total debt/total equity--
Total debt/total capital1.32
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.